Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.50.90 CHF
Change Today +0.95 / 1.90%
Volume 975.0
As of 11:43 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

bachem holding ag-reg b (BANB) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/30/15 - SFr.53.11
52 Week Low
01/23/15 - SFr.40.86
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BACHEM HOLDING AG-REG B (BANB)

Related News

No related news articles were found.

bachem holding ag-reg b (BANB) Related Businessweek News

No Related Businessweek News Found

bachem holding ag-reg b (BANB) Details

Bachem Holding AG, a technology-based biochemicals company, provides services to the pharmaceutical and biotechnology industries primarily in Europe and North America. It develops and manufactures peptide and small molecule active pharmaceutical ingredients (APIs), as well as biochemicals for research purposes. The company offers research products, which include catalog products comprising amino acid derivatives, peptides, and other biochemicals in various packaging sizes for peptide research, small scale peptide synthesis, or other research area; custom synthesis service for peptides and amino acids; sterile peptides under the Clinalfa brand; and glycosylated peptides to improve drug properties. It also provides API products comprising generic APIs used in the fields of cancer, diabetes, obesity, fertility, and others; and new chemical entities. In addition, the company offers customer support services, such as formulation development; sterile tox-vials; compatibility studies; stress tests; post-release stability studies; chemistry, manufacturing, and control documentation for investigational medicinal product dossier and investigational new drug services; and other services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.

821 Employees
Last Reported Date: 08/28/15
Founded in 1971

bachem holding ag-reg b (BANB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.396.0K
Compensation as of Fiscal Year 2014.

bachem holding ag-reg b (BANB) Key Developments

Bachem and Initiative for Life Sciences Extend Their Collaboration in Japan by an Exclusive Agency Agreement

Bachem and Initiative for Life Sciences announced that they will strengthen their co-marketing efforts in Japan. The two companies have been establishing a close collaboration for more than a decade, already. Based on a Sales and Marketing agreement which was signed in 2012, ILS is providing Bachem manufactured Active Pharmaceutical Ingredients (APIs) to Japanese customers. In the course of the acquisition of American Peptide Company Inc., based in California USA, and its transfer from ILS to Bachem, both companies underlined their intentions to extend the current business relations. Under the agreement reached, ILS will be the Exclusive Agent for Japan for all peptide-based products of the Bachem Group; this applies to non-GMP research chemicals as well as for cGMP grade APIs. In addition, ILS will register Drug Master Files in Japan for APIs manufactured by Bachem. They are a highly reliable source of both research grade peptides from catalog or custom synthesis and cGMP manufactured APIs from small to very large scale.

Bachem Holding AG Announces Group Earnings Results for the First Half Year Ended June 30, 2015; Provides Earnings Guidance for 2015

Bachem Holding AG announced group earnings results for the first half year ended June 30, 2015. The company increased its sales by about 15% to nearly CHF 100 million in the first half of 2015 compared to CHF 86.7 million a year ago. Group sales in local currency (LC) for the first half were higher than in any other half-year period since the company's founding. Generics sales rose by approx. 9% in LC to CHF 49.3 million and sales of research ingredients were also very strong in both the catalog products and custom synthesis business. EBITDA was CHF 26.8 million against CHF 25.5 million a year ago. EBIT was CHF 17.6 million against CHF 16.4 million a year ago. Net income was CHF 12.6 million or CHF 0.93 per share against CHF 12.4 million or CHF 0.92 per share a year ago. Cash flows from operating activities were CHF 29.4 million against CHF 19.3 million a year ago. The company reported management priorities during the second half of the year 2015 will focus on the steady integration of APC and further investment in the capacity expansion at all existing sites, to accommodate future growth. Due to the record-high order backlog, the company will strengthen its teams in Switzerland, UK and the US. Management confirms its annual target for 2015. Based on a stable economic environment and current exchange rates, 2015 is expected to be a very good year. Including APC, the company expects sales growth in local currencies of about 10% and a further improvement in profitability.

Bachem Holding AG Announces Earnings Results for the Year 2014

Bachem Holding AG announced earnings results for the year 2014. For the year, sales were CHF 183.9 million against CHF 170.7 million a year ago. EBITDA was CHF 55.1 million against CHF 47.4 million a year ago. EBIT was CHF 35.9 million against CHF 29.5 million a year ago. Net income was CHF 29.1 million against CHF 23.6 million a year ago. Earnings per share were CHF 2.15 against CHF 1.75 a year ago. Cash flow from operating activities was CHF 47.2 million against CHF 49.2 million a year ago. Return on equity was 8.5% against 7.0 % a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BANB:SW SFr.50.90 CHF +0.95

BANB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BANB.
View Industry Companies

Industry Analysis


Industry Average

Valuation BANB Industry Range
Price/Earnings 22.4x
Price/Sales 3.3x
Price/Book 2.0x
Price/Cash Flow 11.2x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BACHEM HOLDING AG-REG B, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at